ESC 2022: Risk score predicts mortality for AF patients after TAVI

The risk score is a product of the ENVISAGE-TAVI AF trial, which compared the safety and efficacy of the direct oral anticoagulant (DOAC) edoxaban with vitamin K antagonists (VKAs) in AF patients with an indication for oral anticoagulation after TAVI. George Dangas (The Zena and Michael A. Wiener Cardiovascular Institute at the Icahn School of Medicine at Mount Sinai, New York, USA) presented findings of the investigation as a late-breaking clinical trial at the European Society of Cardiology (ESC) 2022 congress (26–29 August, Barcelona, Spain).

“Our study focuses solely on high-risk TAVI patients with atrial fibrillation, which is a well-recognised surrogate of unfavourable prognosis,” said Dangas. “Although past research has been mostly focused on procedure risks, this new risk assessment tool focuses on how to stratify patients after completion of successful TAVI when they are ready for discharge, to improve outcomes.”

Click here to continue reading :

Παλαιότερα άρθρα